Drug intelligence / Profile preview

Bifidobacterium animalis subsp. lactis BB-12 + Lactobacillus acidophilus LA-5 + Lactobacillus rhamnosus GG (Norwegian University of Science and Technology)

Development stage: Preclinical
Lead developer: Chr. Hansen
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

A probiotic combination of three specific bacterial strains: *Bifidobacterium animalis subsp. lactis* BB-12 (Bb-12), *Lactobacillus acidophilus* LA-5 (La-5), and *Lactobacillus rhamnosus* GG (LGG). This combination was investigated in the ProPACT clinical trial for the primary prevention of atopic dermatitis in infants when administered to mothers during the perinatal period (from 36 weeks of gestation until 3 months postnatal). The trial demonstrated an approximate 40% relative risk reduction in the cumulative incidence of atopic dermatitis in children at 2 years of age. Probiotics are believed to exert their effects by modulating the gut microbiome and the host's immune system, promoting a healthy immune balance. The product used in the trial was a probiotic milk supplied by Tine BA.

Other names: Bifidobacterium animalis subsp. lactis + Lactobacillus acidophilus + Lactobacillus rhamnosus GG

Beyond the preview

Go deeper on Bifidobacterium animalis subsp. lactis BB-12 + Lactobacillus acidophilus LA-5 + Lactobacillus rhamnosus GG (Norwegian University of Science and Technology).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bifidobacterium animalis subsp. lactis BB-12 + Lactobacillus acidophilus LA-5 + Lactobacillus rhamnosus GG (Norwegian University of Science and Technology).

Explore the full profile